Navigation Links
Varian Medical Systems to Showcase Advanced Technologies for Treating Cancer with Image-Guided Radiotherapy and Radiosurgery at JASTRO Meeting in Tokyo, Japan
Date:11/20/2012

TOKYO, Nov. 20, 2012 /PRNewswire/ -- Varian Medical Systems, Inc. (NYSE: VAR), the leading manufacturer of medical devices for treating cancer, will exhibit the company's advanced technologies for image-guided radiotherapy and radiosurgery at the 25th Annual Meeting of the Japanese Society for Therapeutic Radiology and Oncology (JASTRO) here later this week.  During the meeting, Varian will also sponsor a luncheon seminar on the latest developments in stereotactic radiosurgery and stereotactic body radiotherapy—quick and non-invasive procedures that use high-energy X-rays to treat tumors in the brain or body.

Varian's booth at the meeting will showcase the company's latest products, including the TrueBeam™ medical linear accelerator for image-guided radiotherapy and radiosurgery, offering the high dose delivery rates, precision, and speed needed for precise radiosurgery and stereotactic body radiotherapy procedures.Varian personnel will also be on hand to demonstrate the latest releases of the ARIA® oncology information and Eclipse™ treatment planning software systems.  ARIA is a comprehensive information management solution that streamlines clinical processes, improves workflow, eliminates paper charts, and automates many aspects of managing complex cancer treatments.

"ARIA 11—the latest release—has been designed so that clinicians can personalize their home screen to easily access what they need, at the appropriate level of detail," said Makoto Yamada, sales manager for Varian in Japan.  "ARIA is now also more tightly integrated with the Eclipse system, enabling users to access both applications from a single workspace.  Clinics can configure the system to guide personnel through their daily tasks, and can set up workflows to incorporate safety checks as another quality assurance measure."

Varian Symposium on Stereotactic RadiosurgeryVarian will also sponsor a luncheon symposium on November 24, on the topic of stereotactic radiosurgery and stereotactic body radiotherapy (SBRT).  These quick and non-invasive procedures use carefully shaped high-energy X-ray beams to treat tumors in the brain or body.  Benjamin Slotman, MD, PhD, professor and chairman of the Department of Radiation Oncology at VU University Medical Center in Amsterdam, the Netherlands, will detail his clinical experience treating patients with these approaches, using Varian's TrueBeam™ system and its High Intensity Mode for delivering very high doses with precision and speed.

Dr. Slotman is an international expert in the field of stereotactic irradiation, the treatment of small cell lung cancer, and the early clinical implementation of new technologies.  He has co-authored more than 200 peer reviewed publications, many on the treatment of non-small cell lung cancer using stereotactic approaches.[1]  Dr. Slotman is currently serving as principal investigator of a multicenter randomized trial on the role of thoracic irradiation in lung cancer patients.  He is also the associate editor of the Journal of Radiosurgery and SBRT.

The symposium will be chaired by Hiroki Shirato, M.D., Ph.D., professor and chairman of the Department of Radiation Medicine at the Hokkaido University Graduate School of Medicine.  Dr. Shirato is an internationally-known expert in the management of tumor motion, a very important aspect of treating cancer with stereotactic body radiotherapy, since tumors in the body often move during treatment due to respiration or other normal physiological processes.

[1] Some representative publications:

  • Slotman BJ, Senan S. Radiotherapy in small---cell lung cancer: lessons learned and future directions. Int J Radiat Oncol Biol Phys 79, 998---1003, 2011.
  • Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF, Senan S. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):348-53.
  • Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non---small---cell lung cancer: a retrospective analysis. Lancet Oncol. 2012 Jun 21. [Epub ahead of print]
  • About Varian Medical Systems
    Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes, digital detectors, and image processing workstations for X-ray imaging in medical, scientific, and industrial applications and also supplies high-energy X-ray devices for cargo screening and non-destructive testing applications.  Varian Medical Systems employs approximately 6,100 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.FOR INFORMATION CONTACT:UNITED STATES

    JAPANMeryl Ginsberg

    Yayoi Shimizu Tel: +1.650.424.6444

    Tel: +81-3-4486-5010meryl.ginsberg@varian.com

    yayoi.shimizu@varian.com


    '/>"/>
    SOURCE Varian Medical Systems, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
    2. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
    3. Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer
    4. U.S. Government Supports Phase 3 Study of Bavarian Nordics Smallpox Vaccine
    5. Varian X-Ray Products Business Launches On-Line Product Finder for Customers
    6. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
    7. Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
    8. Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2012
    9. Researchers Discover All-Natural Weapon In The War Against Ovarian Cancer
    10. Varian Medical Systems CEO Timothy E. Guertin Announces Plans to Retire; Board of Directors Names Dow R. Wilson as Successor
    11. Varian Medical Systems Board of Directors Authorizes Repurchase of Additional 8 Million Shares of Stock through Calendar Year 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/15/2017)... -- Axium Pharmaceuticals Inc., the creator of the drug Truveta for ... of an IPO. The United States ... of a prescription epilepsy drug being $450.00-$1200.00 for a one month supply. ... AXIUM PHARMACEUTICALS, INC ... staggering figure is the fact that Americans spent $42 billion on anxiety ...
    (Date:8/14/2017)... Israel , Aug. 15, 2017  BrainStorm ... adult stem cell technologies for neurodegenerative diseases, announced financial ... "We are in ... 3 trial to investigate NurOwn ® in ALS," ... Officer of BrainStorm. "We have agreements with Mass. General ...
    (Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
    Breaking Medicine Technology:
    (Date:8/18/2017)... , ... August 18, 2017 , ... The Golseth Agency, ... the Dallas/Fort Worth area, is spearheading a regional charity campaign organized to provide support ... In early June of this year, Christina and her children returned from out of ...
    (Date:8/18/2017)... , ... August 18, 2017 , ... ... highly trained practitioners specializing in bioidentical hormone replacement therapy and integrative medicine, has ... imbalance and conditions of aging, such as menopause, andropause, thyroid disorder and adrenal ...
    (Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage ... up its marketing efforts with its product now available through Jet.com. , After ... public. The effervescent powdered drink is designed to quickly detox the body thereby avoiding ...
    (Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... numbers and call tracking and monitoring solutions, announced today the launch of a ... include a modern navigation and aesthetic, fully responsive design, and an enhanced search ...
    (Date:8/18/2017)... ... August 18, 2017 , ... “Dangerous Inheritance”: a mystery about ... Winters. Diane is from Southwest Nebraska where she was raised on a farm. ... The story is fictional, but the friendships and mantra of ‘neighbors helping neighbors’ ...
    Breaking Medicine News(10 mins):